Laparoscopic ice slurry coolant for renal hypothermia.

M. Orvieto,K. Zorn,Mark B. Lyon,Stephen R Tohurst,D. Rapp,Albert A. Mikhail,J. Oras,Hyunjin Son,K. Kasza,C. Brendler,A. Shalhav

DOI: https://doi.org/10.1016/J.JURO.2006.08.082

2006-04-01

Abstract:

What problem does this paper attempt to address?

Pathogenesis of obliterative bronchiolitis in rat heterotopic tracheal allografts : An experimental approach to chronic lung allograft rejection

E. Kallio

Abstract:
Relative Cardiovascular and Gastrointestinal Safety of Non-selective Non-steroidal Anti-inflammatory Drugs Versus Cyclo-oxygenase-2 Inhibitors

José Pedro Henriques Patrício,Jorge Pinto Pereira Barbosa,Rui Miguel Monteiro Ramos,Nuno Filipe Pimenta Antunes,Pedro Carlos Santos de Melo

DOI: https://doi.org/10.1007/s40261-013-0052-6

2013-01-22

Clinical Drug Investigation

Abstract:Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used in clinical practice, and are considered a first-line option for pain management. However, non-selective NSAIDs (nsNSAIDs) and new generation NSAIDs named cyclo-oxygenase-2 inhibitors (coxibs) are very different from one another and their cardiovascular and gastrointestinal safety profiles may influence prescribing. This article resulted from a search of MEDLINE/Pubmed, Cochrane Library, Bandolier, Medscape and Trip database, up to June 2011. Key words included non-steroidal anti-inflammatory, coxib and safety, with the purpose of reviewing the gastrointestinal and cardiovascular safety issues of NSAIDS and the main aspects that differentiate both classes. Selective coxibs are associated with a more favourable gastrointestinal safety profile than nsNSAIDs. In terms of the risk of cardiovascular events, there seems to be a class effect for all NSAIDs with the possible exception of naproxen. The proper usage guidelines for NSAIDs detail the importance of risk factors for each patient in addition to the differences between classes. Patients with high cardiovascular or gastrointestinal risk should avoid using NSAIDs. These medications should be used at the minimum effective dose and for the shortest time possible in all patients.

pharmacology & pharmacy
Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration

S Kawai

DOI: https://doi.org/10.1007/s000110050291

Abstract:Severe gastro-intestinal complications are a major cause of NSAID-induced deaths in cases of rheumatoid arthritis. We measured COX selectivity by using an intact cell assay system, and found that NS-398 is a highly COX-2-selective inhibitor. Meloxicam, etodolac and diclofenac also showed high COX-2 selectivity. Zaltoprofen, loxoprofen-SRS (active metabolite of loxoprofen), 6-MNA (active metabolite of nabumetone) and ibuprofen showed intermediate COX-2 selectivity. The lowest COX-2 selectivities, which means the highest COX-1 selectivities, were observed in indomethacin, aspirin, and oxaprozin. There appears to be a good relationship between our data and some clinical data of severe gastro-intestinal toxicity. The more a given NSAID is selective for COX-2, the safer it is for clinical use. In conclusion, to anticipate the safety of NSAIDs, we find that an intact cell assay system, using human cells for measurement of COX selectivity, may be more useful than using direct enzyme assay systems.
Metabolomic Response to Non-Steroidal Anti-Inflammatory Drugs

Soumita Ghosh,Nick Lahens,Kayla Barekat,Soon-Yew Tang,Katherine N. Theken,Emanuela Ricciotti,Arjun Sengupta,Robin Joshi,Frederic D. Bushman,Aalim Weljie,Tilo Grosser,Garret A FitzGerald

DOI: https://doi.org/10.1101/2024.11.26.625478

2024-12-02

Abstract:Non-steroidal anti-inflammatory drugs (NSAIDs) are popular choices for the mitigation of pain and inflammation; however, they are accompanied by side effects in the gastrointestinal and cardiovascular systems. We compared the effects of naproxen, a traditional NSAID, and celecoxib, a cyclooxygenase -2 (Cox-2) inhibitor, in humans. Our findings showed a decrease in tryptophan and kynurenine levels in plasma of volunteers treated with naproxen. We further validated this result in mice. Additionally, we find that the depression of tryptophan was independent of both Cox-1 and Cox-2 inhibition, but rather was due to the displacement of bound tryptophan by naproxen. Supplementation of tryptophan in naproxen-treated mice rescued fecal blood loss and inflammatory gene expression driven by IL-1β in the heart.

Systems Biology
Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs

Shuang Liang,Xianying Wang,Xiuqing Zhu

DOI: https://doi.org/10.3389/fphar.2024.1455212

2024-09-04

Abstract:Background and aim: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat fever, pain, and inflammation. Concerns regarding their cardiovascular safety have been raised. However, the underlying mechanism behind these events remains unknown. We aim to investigate the cardiovascular safety signals and receptor mechanisms of NSAIDs, employing a comprehensive approach that integrates pharmacovigilance and pharmacodynamics. Methods: This study utilized a pharmacovigilance-pharmacodynamic approach to evaluate the cardiovascular safety of NSAIDs and explore potential receptor mechanisms involved. Data were analyzed using the OpenVigil 2.1 web application, which grants access to the FDA Adverse Event Reporting System (FAERS) database, in conjunction with the BindingDB database, which provides target information on the pharmacodynamic properties of NSAIDs. Disproportionality analysis employing the Empirical Bayes Geometric Mean (EBGM) and Reporting Odds Ratio (ROR) methods was conducted to identify signals for reporting cardiovascular-related adverse drug events (ADEs) associated with 13 NSAIDs. This analysis encompassed three System Organ Classes (SOCs) associated with the cardiovascular system: blood and lymphatic system disorders, cardiac disorders, and vascular disorders. The primary targets were identified through the receptor-NSAID interaction network. Ordinary least squares (OLS) regression models explored the relationship between pharmacovigilance signals and receptor occupancy rate. Results: A total of 201,231 reports of cardiovascular-related ADEs were identified among the 13 NSAIDs. Dizziness, anemia, and hypertension were the most frequently reported Preferred Terms (PTs). Overall, nimesulide and parecoxib exhibited the strongest signal strengths of ADEs at SOC levels related to the cardiovascular system. On the other hand, our data presented naproxen and diclofenac as drugs of comparatively low signal strength. Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) were identified as central targets. OLS regression analysis revealed that the normalized occupancy rate for either COX-1 or COX-2 was significantly inversely correlated with the log-transformed signal measures for blood and lymphatic system disorders and vascular disorders, and positively correlated with cardiac disorders and vascular disorders, respectively. This suggests that higher COX-2 receptor occupancy is associated with an increased cardiovascular risk from NSAIDs. Conclusion: Cardiovascular safety of NSAIDs may depend on pharmacodynamic properties, specifically, the percentage of the occupied cyclooxygenase isoenzymes. More studies are needed to explore these relations and improve the prescription process.
Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing

Afaf A. El-Malah,Magdy M. Gineinah,Pran Kishore Deb,Ahdab N. Khayyat,Monika Bansal,Katharigatta N. Venugopala,Anfal S. Aljahdali

DOI: https://doi.org/10.3390/ph15070827

IF: 4.6

2022-07-04

Pharmaceuticals

Abstract:The introduction of selective COX-2 inhibitors (so-called 'coxibs') has demonstrated tremendous commercial success due to their claimed lower potential of serious gastrointestinal adverse effects than traditional NSAIDs. However, following the repeated questioning on safety concerns, the coxibs 'controversial me-too' saga increased substantially, inferring to the risk of cardiovascular complications, subsequently leading to the voluntary withdrawal of coxibs (e.g., rofecoxib and valdecoxib) from the market. For instance, the makers (Pfizer and Merck) had to allegedly settle individual claims of cardiovascular hazards from celecoxib and valdecoxib. Undoubtedly, the lessons drawn from this saga revealed the flaws in drug surveillance and regulation, and taught science to pursue a more integrated translational approach for data acquisition and interpretation, prompting science-based strategies of risk avoidance in order to sustain the value of such drugs, rather than their withdrawal. Looking forward, coxibs are now being studied for repurposing, given their possible implications in the management of a myriad of diseases, including cancer, epilepsy, psychiatric disorders, obesity, Alzheimer's disease, and so on. This article briefly summarizes the development of COX-2 inhibitors to their market impression, followed by the controversy related to their toxicity. In addition, the events recollected in hindsight (the past lessons), the optimistic step towards drug repurposing (the present), and the potential for forthcoming success (the future) are also discussed.

pharmacology & pharmacy,chemistry, medicinal
Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

Zhiran Ju,Menglan Li,Junde Xu,Daniel C. Howell,Zhiyun Li,Fen-Er Chen

DOI: https://doi.org/10.1016/j.apsb.2022.01.002

IF: 14.903

2022-01-01

Acta Pharmaceutica Sinica B

Abstract:Cyclooxygenases play a vital role in inflammation and are responsible for the production of prostaglandins. Two cyclooxygenases are described, the constitutive cyclooxygenase-1 and the inducible cyclooxygenase-2, for which the target inhibitors are the non-steroidal anti-inflammatory drugs (NSAIDs). Prostaglandins are a class of lipid compounds that mediate acute and chronic inflammation. NSAIDs are the most frequent choices for treatment of inflammation. Nevertheless, currently used anti-inflammatory drugs have become associated with a variety of adverse effects which lead to diminished output even market withdrawal. Recently, more studies have been carried out on searching novel selective COX-2 inhibitors with safety profiles. In this review, we highlight the various structural classes of organic and natural scaffolds with efficient COX-2 inhibitory activity reported during 2011-2021. It will be valuable for pharmaceutical scientists to read up on the current chemicals to pave the way for subsequent research.

pharmacology & pharmacy
The Second Generation of COX-2 Inhibitors

Dirk O. Stichtenoth,Jürgen C. Frölich,J??rgen C. Fr??lich

DOI: https://doi.org/10.2165/00003495-200363010-00003

2003-01-01

Drugs

Abstract:The discovery of two cyclooxygenase (COX)-isoenzymes, a constitutive OX-1, serving homeostatic prostanoid synthesis, and an inducible COX-2, responsible for proinflammatory prostanoid production, led to the development of new non-steroidal anti-inflammatory drugs (NSAIDs), the selective COX-2 inhibitors, promising minimal NSAID-typical toxicity with full anti-inflammatory efficacy.So far, the strategy of selective COX-2 inhibition has been successful. Selective COX-2 inhibitors have significantly less gastrotoxicity and no effects on platelet aggregation. However, with regard to renal adverse events, selective COX-2 inhibitors do not offer a clinically relevant advantage over non-selective inhibitors. Moreover, concerns over the cardiovascular risk of selective COX-2 inhibitors have recently been raised.The second generation of COX-2 inhibitors with higher COX-2 selectivity was developed with the promise of further reduction of NSAID-typical adverse effects. The leading compounds are valdecoxib, parecoxib, etoricoxib and lumaricoxib. At the present time they have proven efficacy for the treatment of pain and inflammation. Parecoxib as a parenteral, highly selective COX-2 inhibitor has the potential to become the NSAID of choice for treatment of postoperative pain.In clinical trials, valdecoxib, parecoxib, etoricoxib and lumaricoxib have caused no more endoscopic ulcers than placebo. However, to date, no data on the clinically relevant endpoints perforation, symptomatic ulcer and bleeding are available. Furthermore, no definite conclusions on renal and cardiovascular safety are possible. Current evidence points to a marginal, if any, gain of safety compared with the first generation of COX-2 inhibitors. However, trials with the new COX-2 inhibitors offer the chance to address these open questions of highly selective COX-2 inhibition; that is, thrombogenic risk, sodium and water retention, and interference with tissue repair, in particular, healing of mucosal damage.

pharmacology & pharmacy,toxicology
Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac

Chris Walker

DOI: https://doi.org/10.1155/2018/1302835

2018-12-09

International Journal of Rheumatology

Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely used for the treatment of arthritic conditions. Drugs in this heterogeneous class alleviate pain and inflammation by inhibiting cyclooxygenase-2 (COX-2). Cyclooxygenase-1 (COX-1) inhibition has traditionally been associated with increased gastrointestinal (GI) harm, whereas increased COX-2 selectivity has more recently become associated with greater risk of cardiovascular (CV) harm. When the entirety of data is considered, NSAIDs can be seen to exhibit a range of COX isoform selectivity, with all oral NSAIDs appearing to be associated with an increase in CV events. This review focuses on a comparison of the efficacy and the GI and CV safety profiles of three commonly used NSAIDs—celecoxib, etoricoxib, and diclofenac—using direct comparisons where available. While all three treatments are shown to have comparable efficacy, there are differences in their safety profiles. Both celecoxib and etoricoxib are associated with less GI harm than diclofenac despite the similarity of its COX-2 selectivity to celecoxib. Each of the three medicines under consideration is associated with a similar overall risk of CV events (fatal and nonfatal heart attacks and strokes). However, there are consistent differences in effects on blood pressure (BP), reported both from trials using ambulatory techniques and from meta-analyses of randomized trials, reporting investigator determined effects, with etoricoxib being associated with a greater propensity to destabilize BP control than either diclofenac or celecoxib.
Safety profiles of leading nonsteroidal anti-inflammatory drugs

R Rothstein

DOI: https://doi.org/10.1016/s0002-9343(98)00280-0

1998-11-02

Abstract:Recently introduced nonsteroidal anti-inflammatory drugs (NSAIDs) have capitalized on new formulations or unique physical and pharmacologic properties in an attempt to provide a greater margin of gastrointestinal (GI) safety. The use of enteric coatings and nonoral or pro-drug formulations have not necessarily provided the expected safety, but other properties have been identified that appear to be more promising. However, as demonstrated by oxaprozin, considered to be one of the least safe NSAIDs but one of the leading drugs on the US market, success may not be dependent on safety. In contrast, the improved tolerability of 2 other new NSAIDs, nabumetone and etodolac, has been established in clinical trials and limited postmarketing surveillance. This improved tolerability is probably associated with several pharmacologic properties that have been suggested to contribute to GI safety: (1) nonacidic pro-drug formulation; (2) lack of enterohepatic recirculation; (3) a short plasma half-life; and (4) preferential inhibition of cyclo-oxygenase-2 (COX-2). Although these factors may not improve efficacy, their incorporation into the design of drugs suggests that safer NSAIDs may be a clinical reality. However, the safety and clinical value of any new drug for the general population will be validated only through extensive postmarketing surveillance.
Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective

Sandhya Chahal,Payal Rani,Kiran,Jayant Sindhu,Gaurav Joshi,Aravindhan Ganesan,Subha Kalyaanamoorthy,Mayank,Parvin Kumar,Rajvir Singh,Arvind Negi

DOI: https://doi.org/10.1021/acsomega.3c00692

IF: 4.1

2023-05-09

ACS Omega

Abstract:Innate inflammation beyond a threshold is a significant problem involved in cardiovascular diseases, cancer, and many other chronic conditions. Cyclooxygenase (COX) enzymes are key inflammatory markers as they catalyze prostaglandins production and are crucial for inflammation processes. While COX-I is constitutively expressed and is generally involved in "housekeeping" roles, the expression of the COX-II isoform is induced by the stimulation of different inflammatory cytokines and also promotes the further generation of pro-inflammatory cytokines and chemokines, which affect the prognosis of various diseases. Hence, COX-II is considered an important therapeutic target for drug development against inflammation-related illnesses. Several selective COX-II inhibitors with safe gastric safety profiles features that do not cause gastrointestinal complications associated with classic anti-inflammatory drugs have been developed. Nevertheless, there is mounting evidence of cardiovascular side effects from COX-II inhibitors that resulted in the withdrawal of market-approved anti-COX-II drugs. This necessitates the development of COX-II inhibitors that not only exhibit inhibit potency but also are free of side effects. Probing the scaffold diversity of known inhibitors is vital to achieving this goal. A systematic review and discussion on the scaffold diversity of COX inhibitors are still limited. To address this gap, herein we present an overview of chemical structures and inhibitory activity of different scaffolds of known COX-II inhibitors. The insights from this article could be helpful in seeding the development of next-generation COX-II inhibitors.

chemistry, multidisciplinary
Pharmacogenomics of Hypersensitivity to Non-steroidal Anti-inflammatory Drugs

Hoang Kim Tu Trinh,Le Duy Pham,Kieu Minh Le,Hae-Sim Park

DOI: https://doi.org/10.3389/fgene.2021.647257

IF: 3.7

2021-06-25

Frontiers in Genetics

Abstract:Non-steroidal anti-inflammatory drugs (NSAIDs) are extensively prescribed in daily clinical practice. NSAIDs are the main cause of drug hypersensitivity reactions all over the world. The inhibition of cyclooxygenase enzymes by NSAIDs can perpetuate arachidonic acid metabolism, shunting to the 5-lipoxygenase pathway and its downstream inflammatory process. Clinical phenotypes of NSAID hypersensitivity are diverse and can be classified into cross-reactive or selective responses. Efforts have been made to understand pathogenic mechanisms, in which, genetic and epigenetic backgrounds are implicated in various processes of NSAID-induced hypersensitivity reactions. Although there were some similarities among patients, several genetic polymorphisms are distinct in those exhibiting respiratory or cutaneous symptoms. Moreover, the expression levels, as well as the methylation status of genes related to immune responses were demonstrated to be involved in NSAID-induced hypersensitivity reactions. There is still a lack of data on delayed type reactions. Further studies with a larger sample size, which integrate different genetic pathways, can help overcome current limitations of gen etic/epigenetic studies, and provide valuable information on NSAID hypersensitivity reactions.

genetics & heredity
NSAID mechanism of action: the role of intracellular pharmacokinetics

L. G. Herbette,M. Vecchiarelli,G. Trummlitz

DOI: https://doi.org/10.1007/978-94-010-9029-2_5

1996-01-01

Abstract:Nonsteroid anti-inflammatory drugs (NSAIDs) are a structurally diverse group of agents with similar therapeutic effects. They reduce pain, fever and inflammation, and are also associated with lowered risks of cardiovascular disease1 and colon cancer2,3. The biological basis for the therapeutic effects of NSAIDs is their ability to inhibit prostaglandin biosynthesis. The NSAIDs specifically target the bifunctional cyclooxygenase enzyme (COX) which is responsible for the initial rate-limiting conversion of arachidonic acid to prostaglandin G (PGG) and its subsequent conversion to PGH2. This is then converted to other prostanoids4,5.
Human and Object Detection in Smoke-filled Space using Millimeter-wave radar based Measurement System

Y. Aoki,Masaki Sakai

DOI: https://doi.org/10.20965/jrm.2006.p0760

2006-08-20

Abstract:In recent years, crisis management's response to terrorist attacks and natural disasters, as well as accelerating rescue operations have become an important issue. In rescue operations of fire disaster, one of the biggest problems is that the firefighter’s view is obstructed by dense smoke. We considered the most important task for firefighters is to understand the inside situation of the dense smoke space. Therefore, we aim to develop a system visualizing the situation of the space. First, we scanned target space by using millimeter-wave radar combined with a gyro sensor. Then, due to detect humans and objects, we construct a 3D map from signal-reflection datasets using 3D image processing techniques. In this paper, we introduce our system and report the results of the measurement experiment in the real smoke space situation.
PIH21 EFFICACY AND SAFETY OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN PATIENTS WITH OSTEOARTHRITIS: A NETWORK META-ANALYSIS

X. Sun,X. Zhen,X. Hu,Y. Gu,Z. Zhao,H. Dong

DOI: https://doi.org/10.1016/j.jval.2020.04.416

IF: 5.156

2020-01-01

Value in Health

Abstract:Non-steroidal anti-inflammatory drug (NSAIDs) are widely prescribed for relief of the symptoms of osteoarthritis. The efficacy and safety of different NSAIDs are still studied, especially between the cyclooxygenase-2 inhibitor (COX-2) and non-selective NSAIDs (ns-NSAIDs). A new Cox-2 NSAID called imrecoxib was approved by China Food and Drug Administration in 2011, and the efficacy and safety compared with other NSAIDs stay unexplored. This study is aimed to access the overall efficacy and safety of imrecoxib, celecoxib (COX-2), diclofenac (ns-NSAIDs) based on the existing literature. 25 randomized controlled trials (RCTs) published from the time of database establishment to Nov 19, 2019 were systematically reviewed in 8 databases, which compared any of imrecoxib, celecoxib, diclofenac and placebo. The primary outcome was the mean change of different drugs on patient’s pain score (VAS mm); the sencondary outcomes were the rate of total adverse events and gastrointestinal (GI) events. The rate of adverse events was adjusted with standardized doses. Literature with less than 4-week treatment duration were excluded. Celecoxib (standardized mean difference [SMD] -0.52 [95%CI -0.96 to -0.09]) was significantly more effective than placebo, while imrecoxib (-0.67 [-1.97 to 0.63]) and diclofenac (-0.49 [-1.06 to 0.08]) were more effective than placebo. Celecoxib (odds ratio [OR] 1.04 [95%CI 0.84 to 1.28]) and diclofenac (1.27 [0.89 to 1.81]) were more unsafe than placebo, whereas imrecoxib was not. Similar results could be found in the analysis of the rate of GI events, celecoxib (1.05 [0.83 to 1.32]) and diclofenac (1.39 [0.95 to 2.03]) were more unsafe than placebo. It seemed that imrecoxib was associated with better efficacy and fewer adverse events. Since there were sparse RCTs have been reported for imrecoxib, the conclusion should be adopted with caution. Meanwhile, a nocebo effect was observed in the analysis of the rate of adverse events, which need further discussion.
Drug Design, Synthesis and Biological Evaluation of Heterocyclic Molecules as Anti-Inflammatory Agents

Jignasa Savjani,Bhavesh Variya,Snehal Patel,Suja Mulamkattil,Harsh Amin,Shital Butani,Ahmed Allam,Jamaan Ajarem,Harsh Shah

DOI: https://doi.org/10.3390/molecules27041262

IF: 4.6

2022-02-14

Molecules

Abstract:Non-steroidal anti-inflammatory drugs (NSAIDs) are generally utilized for numerous inflammatory ailments. The long-term utilization of NSAIDs prompts adverse reactions such as gastrointestinal ulceration, renal dysfunction and hepatotoxicity; however, selective COX-2 inhibitors prevent these adverse events. Various scientific approaches have been employed to identify safer COX-2 inhibitors, as in any case, a large portion of particular COX-2 inhibitors have been retracted from the market because of severe cardiovascular events. This study aimed to develop and synthesize a novel series of indomethacin analogues with potential anti-inflammatory properties and fewer side effects, wherein carboxylic acid moiety was substituted using DCC/DMAP coupling. This study incorporates the docking of various indomethacin analogues to detect the binding interactions with COX-2 protein (PDB ID: 3NT1). MD simulation was performed to measure the stability and flexibility of ligand–protein interactions at the atomic level, for which the top-scoring ligand–protein complex was selected. These compounds were evaluated in vitro for COX enzymes inhibition. Likewise, selected compounds were screened in vivo for anti-inflammatory potential using the carrageenan-induced rat paw oedema method and their ulcerogenic potential. The acute toxicity of compounds was also predicted using in silico tools. Most of the compounds exhibited the potent inhibition of both COX enzymes; however, 3e and 3c showed the most potent COX-2 inhibition having IC50 0.34 μM and 1.39 μM, respectively. These compounds also demonstrated potent anti-inflammatory potential without ulcerogenic liability. The biological evaluation revealed that the compound substituted with 4-nitrophenyl was most active.

chemistry, multidisciplinary,biochemistry & molecular biology
Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right Patient

Neal M. Davies,Neil M. Skjodt

DOI: https://doi.org/10.2165/00003088-200038050-00001

2000-05-01

Clinical Pharmacokinetics

Abstract:Effective use of the growing number of nonsteroidal anti-inflammatory drugs (NSAIDs), a group that has recently been augmented by the introduction of the selective cyclo-oxygenase-2 inhibitors, requires adequate knowledge of their pharmacokinetics.After oral administration, the absorption of NSAIDs is generally rapid and complete. NSAIDs are highly bound to plasma proteins, specifically to albumin (>90%). The volume of distribution of NSAIDs is low, ranging from 0.1 to 0.3 L/kg, suggesting minimal tissue binding. NSAID binding in plasma can be saturated when the concentration of the NSAID exceeds that of albumin.Most NSAIDs are metabolised by the liver, with subsequent excretion into urine or bile. Enterohepatic recirculation occurs when a significant amount of an NSAID or its conjugated metabolites are excreted into the bile and then reabsorbed in the distal intestine. NSAID elimination is not dependent on hepatic blood flow. Hepatic NSAID elimination is dependent on the free fraction of NSAID within the plasma and the intrinsic enzyme activities of the liver. Renal elimination is not an important elimination pathway for NSAIDs, except for azapropazone. The plasma half-life of NSAIDs ranges from 0.25 to >70 hours, indicating wide differences in clearance rates. Hepatic or renal disease can alter NSAID protein binding and metabolism. Some NSAIDs with elimination predominantly via acylglucuronidation can have significantly altered disposition. Pharmacokinetics are also influenced by chronobiology, and many NSAIDs exhibit stereoselectivity.There appear to be relationships between NSAID concentration and effects. At therapeutically equivalent doses, NSAIDs appear to be equally efficacious. The major differences between NSAIDs are their therapeutic half-lives and safety profiles. NSAIDs undergo drug interactions through protein binding displacement and competition for active renal tubular secretion with other organic acids.When choosing the right NSAID for the right patient, individual patient-specific and NSAID-specific pharmacokinetic principles should be considered.

pharmacology & pharmacy
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents

Francis K. L. Chan,Neena S. Abraham,James M. Scheiman,Loren Laine

DOI: https://doi.org/10.1111/j.1572-0241.2008.02200.x

2008-01-01

Abstract:BACKGROUND: Prescribing nonsteroidal antiinflammatory drugs (NSAIDs) is challenging because physicians have to consider gastrointestinal (GI) and cardiovascular (CV) safety issues.OBJECTIVE: The purpose of the study was to determine appropriate NSAID treatment strategies based on different combinations of GI and CV risks.METHODS: The working party comprised a multidisciplinary international panel of 19 experts. Two hundred eighty-eight vignettes were evaluated for the appropriateness of each of six options: naproxen, non-naproxen nonselective NSAIDs, naproxen plus proton pump inhibitor (PPI)/misoprostol, non-naproxen nonselective NSAID plus PPI/misoprostol, cyclooxygenase-2 selective NSAID (coxib), or coxib plus PPI/misoprostol. Using a two-stage modified Delphi process, the panel anonymously ranked the appropriateness of each option from 1 (extremely inappropriate) to 9 (extremely appropriate). Vignettes were considered appropriate if >= 80% of all panelists' scores were 7-9 and inappropriate if >= 80% of all panelists' scores were 1-3.RESULTS: The panel rated nonselective NSAIDs as appropriate when the patient had average GI risk (< 70 yr of age; no prior upper GI event; no corticosteroids, antithrombotic agents, anticoagulants). In patients with GI risk factors, cotherapy with a PPI/misoprostol was appropriate. Either a nonselective NSAID or a coxib was rated appropriate in patients with average CV risk; naproxen was preferred in patients with high CV risk. None of the options was considered appropriate in patients with multiple GI risk factors and high CV risk.CONCLUSIONS: The initial choice of an NSAID (naproxen vs. others) relates to a patient's CV risk, and the need for therapy to decrease GI complications (PPI/misoprostol or coxibs) is determined by severity and number of GI risk factors.
Working hours and health in nurses of public hospitals according to gender

J. C. Fernandes,L. Portela,R. Griep,L. Rotenberg

DOI: https://doi.org/10.1590/S1518-8787.2017051006808

2017-06-20

Revista de Saúde Pública

Abstract:ABSTRACT OBJECTIVE To assess the association between weekly working hours and self-rated health of nurses in public hospitals in Rio de Janeiro, State of Rio de Janeiro, Brazil. METHODS A total of 3,229 nurses (82.7% of the eligible group) participated in this cross-sectional study, carried out between April 2010 and December 2011. The collection instrument consisted of a self-administered multidimensional questionnaire. The weekly working hours were calculated from a recall of the daily hours worked over seven consecutive days; this variable was categorized according to tertiles of distribution for men and women. The outcome of interest, self-rated health, was categorized into three levels: good (very good and good), regular, and poor (poor and very poor). The statistical analysis of the data included bivariate and multivariate analyses, having as reference group those with short working hours (first tertile). All the analyses were stratified by gender and elaborated using the program SPSS. RESULTS Among women, the group corresponding to the longest working week (more than 60.5 hours per week) were more likely to report regular self-rated health, compared with those with shorter working hours, after adjusting for confounding factors (OR = 1.30; 95%CI 1.02–1.67). Among men, those with average working hours (49.5–70.5 hours per week) were more than twice as likely to rate their health as regular (OR = 2.17; 95%CI 1.08–4.35) compared to those with shorter working hours (up to 49.5 hours). There was no significant association between long working hours and poor self-rated health. CONCLUSIONS The results point to the urgent need to promote interventions in the organization of work and appreciation of the nursing profession, in order to reduce the number of multiple jobs and thus contribute to mitigate potential effects on the health of workers and the quality of care in hospitals.
Cyclooxygenase-2 Inhibitors in Patients with High Gastrointestinal Risk: Are We There Yet?

Vincent Wai-Sun Wong,Francis Ka-Leung Chan

DOI: https://doi.org/10.1007/s00535-008-2260-z

2009-01-01

Journal of Gastroenterology

Abstract:Gastrointestinal complications from the use of nonsteroidal antiinflammatory drugs (NSAIDs) are common and costly. Cyclooxygenase (COX)-2 inhibitors cause fewer gastrointestinal events than nonselective NSAIDs but may still result in peptic ulcer complications in a significant proportion of high-risk patients. The risk can be further reduced by prescribing COX-2 inhibitors together with proton pump inhibitors. Small-bowel injury is also commonly seen in long-term users of COX-2 inhibitors. The potential cardiovascular side effects of most COX-2 inhibitors and NSAIDs pose great challenge to physicians. Further studies are required to optimize the treatment regimen in patients with high cardiovascular and gastrointestinal risk and to decide the best treatment options for patients with small- and large-bowel complications.

Laparoscopic ice slurry coolant for renal hypothermia.

Pathogenesis of obliterative bronchiolitis in rat heterotopic tracheal allografts : An experimental approach to chronic lung allograft rejection

Relative Cardiovascular and Gastrointestinal Safety of Non-selective Non-steroidal Anti-inflammatory Drugs Versus Cyclo-oxygenase-2 Inhibitors

Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration

Metabolomic Response to Non-Steroidal Anti-Inflammatory Drugs

Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs

Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing

Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

The Second Generation of COX-2 Inhibitors

Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac

Safety profiles of leading nonsteroidal anti-inflammatory drugs

Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective

Pharmacogenomics of Hypersensitivity to Non-steroidal Anti-inflammatory Drugs

NSAID mechanism of action: the role of intracellular pharmacokinetics

Human and Object Detection in Smoke-filled Space using Millimeter-wave radar based Measurement System

PIH21 EFFICACY AND SAFETY OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN PATIENTS WITH OSTEOARTHRITIS: A NETWORK META-ANALYSIS

Drug Design, Synthesis and Biological Evaluation of Heterocyclic Molecules as Anti-Inflammatory Agents

Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right Patient

Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents

Working hours and health in nurses of public hospitals according to gender

Cyclooxygenase-2 Inhibitors in Patients with High Gastrointestinal Risk: Are We There Yet?